SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 7/27/2017 2:23:52 PM - Followers: 157 - Board type: Free - Posts Today: 1



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

IDRA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/07/2017 01:09:59 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/07/2017 11:02:36 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/06/2017 04:08:18 PM
IDRA News: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 06/22/2017 04:30:00 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 06/09/2017 04:18:18 PM
PostSubject
#2958   Using market as opportunity for IDRA to test Citrati 07/27/17 02:23:52 PM
#2957   It is all about march 2.10 now. Citrati 07/25/17 10:30:24 AM
#2956   Market structure and all ma's are on our Citrati 07/25/17 10:01:32 AM
#2955   Looking good Would love to see this hold over Cbdpotential 07/25/17 09:44:01 AM
#2954   No doubt I'm more optimistic than ever $idra Cbdpotential 07/24/17 02:44:43 AM
#2953   Well, IDRA still has some perky in it. Citrati 07/20/17 04:23:33 PM
#2952   No joke Cbdpotential 07/15/17 08:20:59 PM
#2951   Agreed. I've been holding for a couple of Phantom Lord 07/12/17 07:06:34 PM
#2950   Thanks Citrati! Let's hope our other baby attilathehunt 07/12/17 07:04:33 PM
#2949   Confirmed closes above 1.97 on the 3 year Citrati 07/12/17 06:58:39 PM
#2948   Nice close above both. Citrati 07/11/17 06:16:06 PM
#2947   Daily 200dma @ $1.84 Cre8tivmynd 07/11/17 12:06:27 PM
#2946   Come on, lets make the 200day support. Citrati 07/11/17 11:20:58 AM
#2945   Next up if confirmation closing (1.80or better) Citrati 07/07/17 04:42:09 PM
#2944   We got the $1.80!!! attilathehunt 07/07/17 04:37:28 PM
#2943   Give it a Friday 1.80 or more close Citrati 07/07/17 12:10:58 PM
#2942   I sense this is about to take off. attilathehunt 07/06/17 01:24:46 PM
#2941   Still fighting with the 50day, but some nice Citrati 07/06/17 01:23:18 PM
#2940   Thanks for your input. I'm trying not to Cre8tivmynd 06/30/17 10:58:51 AM
#2939   If todays negativity continues and the close is Citrati 06/30/17 10:35:09 AM
#2938   I'd be interested to know what your technical Cre8tivmynd 06/30/17 09:59:10 AM
#2937   Time will tell, but for now it looks Citrati 06/29/17 12:11:16 AM
#2936   What an ugly day. Probably thanks to weakness Cre8tivmynd 06/27/17 03:54:24 PM
#2935   Started trading this again after a while away rivervalley 06/26/17 03:50:40 PM
#2934   Wouldn't be surprised to see it touch the Cbdpotential 06/26/17 10:55:11 AM
#2933   Yep, looks like it is just playing with Citrati 06/26/17 10:41:08 AM
#2932   Obviously ;-) hehe Nice buying opportunity today (now) imo Hope Cbdpotential 06/26/17 10:37:20 AM
#2931   I feel as a business only strategy. That chriswolff 06/26/17 06:02:21 AM
#2930   2 hours ago Motley Fool quoted another article Citrati 06/24/17 01:31:34 PM
#2929   Shorts very active Friday, caught by surprise with the gipper 06/24/17 08:18:08 AM
#2928   Surprised this isn't flying. Mms? docprep 06/23/17 02:23:46 PM
#2927   Congrats Those with impatience and/or little dd will be Citrati 06/23/17 12:45:47 AM
#2926   I've been adding recently And a bit frustrating watching Cbdpotential 06/22/17 10:56:50 PM
#2925   Key phrase is "we are increasingly encouraged with jaybe 06/22/17 09:40:45 PM
#2924   Idera Announces FDA Orphan Drug Designation for IMO-2125 Cbdpotential 06/22/17 08:49:11 PM
#2923   Nice! Cbdpotential 06/22/17 08:48:28 PM
#2922   Orphan Drug Designation. Nice 15% pop after hours... Stockdoggy 06/22/17 06:24:25 PM
#2921   No chart? attilathehunt 06/20/17 03:30:14 PM
#2920   Several happy chart indicators. Citrati 06/20/17 03:28:26 PM
#2919   Come on IDRA make this the bottom. Citrati 06/15/17 11:25:35 PM
#2918   It may be bottoming, but it doesn't seem Cre8tivmynd 06/13/17 01:46:25 PM
#2917   So far today price tested our recent low Citrati 06/12/17 11:07:26 AM
#2916   Actually, IMO, the chart looks to be bottoming Citrati 06/07/17 06:36:29 PM
#2915   It's not looking promising. Cre8tivmynd 06/07/17 02:02:00 PM
#2914   There is day 2 for price above the 4ema. Citrati 06/02/17 11:12:20 PM
#2913   Good call rocket. attilathehunt 06/02/17 02:18:53 PM
#2912   Added 1.73 $IDRA , Greece ;-) Cbdpotential 06/02/17 01:52:24 PM
#2911   Couldn't help but buy a slug at 1.57 rocketeer357 05/31/17 12:52:54 AM
#2910   You would think we are about there, but Citrati 05/30/17 03:23:56 PM
#2909   Geez...@ $1.57, How oversold does this need to go?? Cre8tivmynd 05/30/17 02:47:49 PM
PostSubject